ESC 365 - Question and answers - Addressing cardiovascular risk in type 2 diabetes - The LEADER trial.

ESC Premium Access

Question and answers - Addressing cardiovascular risk in type 2 diabetes - The LEADER trial.

Session: Addressing cardiovascular risk in type 2 diabetes - The LEADER trial

Topic: Diabetes management

Speaker: Professor L. Ryden (Stockholm, SE)

Sponsored by Novo Nordisk

Event: ESC Congress 2016

Congress Presentation

Add to my library

About the speaker

Professor Lars Ryden

Karolinska Institute, Stockholm (Sweden)

37 presentations

1 follower

4 more presentations in this session

Introduction - Cardiovascular risk in diabetes and cardiovascular outcomes trials - Where do we come from?

Speaker: Professor L. Ryden (Stockholm, SE)

LEADER – Cardiovascular outcomes & the cardiologist’s perspective.

Speaker: Professor S. Nissen (Cleveland, US)

LEADER from the diabetologist’s perspective.

Speaker: Professor J. Petrie (Glasgow, GB)

Cardiovascular outcomes trials in diabetes – What have we learned?

Speaker: Doctor M. Husain (Toronto, CA)

Access the full session

Addressing cardiovascular risk in type 2 diabetes - The LEADER trial

Speakers: Professor L. Ryden, Professor L. Ryden, Professor S. Nissen, Professor J. Petrie, Doctor M. Husain

About the event

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources